Gilead Sciences

board

Gilead Sciences is a company.

select Filter
All
Business
Culture
Environment
Politics
Research
Health

Key facts

Latest news (see all)

CymaBay shares jumped nearly 25% to hit a record after the clinical-stage biopharmaceutical company agreed to be acquired by Gilead for $4.3 billion.

Read: The Wall Street Journal

2024-02-13

CymaBay Therapeutics Shares Hit All-Time High on Gilead Deal

Read: The Wall Street Journal

2024-02-12

CymaBay Therapeutics Shares Hit All-Time High on Gilead Deal

Read: The Wall Street Journal

2024-02-12

Drugmaker Gilead to acquire CymaBay for $4.3 billion

Read: CNBC News

2024-02-12

Stocks making the biggest moves midday: Vita Coco, Archer-Daniels-Midland, Gilead Sciences and more

Read: CNBC News

2024-01-22

Stocks making the biggest moves midday: Amazon, Lennar, GoodRx, Gilead Sciences and more

Read: CNBC News

2024-01-10

Metrics

Business

assets 68B $
Debt 26.2B $
free cash flow 8,696,380,000.00
market cap 80,337,200,000.00
profits 6.2B $

Visualizations

Datasets

Source

This dashboard is based on data from: Twitter, YAHOO-FIN, YFINANCE

Updated: 1 day ago

License

This content can be used under the CC BY 4.0 license

Going further

We would recommend you have a look at connected dashboards: